نتائج البحث

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.

• Authors : Mazza S; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milan, Italy.; Piazza O Sed N

Subjects: Drug Substitution* ; Treatment Outcome*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacology

• Source: Clinical and translational science [Clin Transl Sci] 2022 Jan; Vol. 15 (1), pp. 172-181. Date of Electronic Publication: 2021 Sep 15.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

• Authors : Peters S; Oncology Department - CHUV, Lausanne University, Lausanne, Switzerland.; Galle PR

Subjects: Safety* ; Treatment Outcome*; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*immunology

• Source: Clinical and translational science [Clin Transl Sci] 2022 Jan; Vol. 15 (1), pp. 141-157. Date of Electronic Publication: 2021 Sep 28.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.

• Authors : Babini A; Hospital Italiano de Córdoba, Córdoba, Argentina.; Cappuccio AM

Subjects: Treatment Outcome*; Adrenal Cortex Hormones/Adrenal Cortex Hormones/Adrenal Cortex Hormones/*administration & dosage ; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*administration & dosage

• Source: Lupus [Lupus] 2020 Oct; Vol. 29 (11), pp. 1385-1396. Date of Electronic Publication: 2020 Aug 14.Publisher: SAGE Publications Country of Publication: England NLM ID: 9204265 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.

• Authors : Van den Nest M; Department for Evidence-based Medicine and Clinical Epidemiology, Donau-Universität Krems, Dr.-Karl-Dorrek-Straße 30, 3500, Krems, Austria. .; Glechner A

Subjects: Administration, Intravenous* ; Injections, Subcutaneous* ; Treatment Outcome*

• Source: Systematic reviews [Syst Rev] 2019 Dec 11; Vol. 8 (1), pp. 321. Date of Electronic Publication: 2019 Dec 11.Publisher: BioMed Central Country of Publication: England NLM ID: 101580575 Publication Model: Electronic Cited Medium: Internet ISSN: 2046-4053

تفاصيل العنوان

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

• Authors : Shikiar R; Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA. ; Willian MK

Subjects: Sickness Impact Profile* ; Treatment Outcome*; Psoriasis/Psoriasis/Psoriasis/*psychology

• Source: Health and quality of life outcomes [Health Qual Life Outcomes] 2006 Sep 27; Vol. 4, pp. 71. Date of Electronic Publication: 2006 Sep 27.Publisher: BioMed Central Country of Publication: England NLM ID: 101153626 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7525

تفاصيل العنوان

Impact of inadequately controlled asthma: a need for targeted therapy?

• Authors : Mehlhop PD; Brody School of Medicine, East Carolina University, 2495 Henby Lane, Greenville, NC 27834, USA. ; Blake K

Subjects: Treatment Outcome*; Anti-Asthmatic Agents/Anti-Asthmatic Agents/Anti-Asthmatic Agents/*therapeutic use ; Asthma/Asthma/Asthma/*drug therapy

• Source: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2004 Jun; Vol. 29 (3), pp. 189-94.Publisher: Country of Publication: England NLM ID: 8704308 Publication Model: Print Cited Medium: Print ISSN: 0269-4727 (Print) Linking ISSN:

تفاصيل العنوان

Infliximab extends the duration until the first surgery in patients with Crohn's disease.

• Authors : Sakatani A; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan.; Fujiya M

Subjects: Treatment Outcome*; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*administration & dosage ; Crohn Disease/Crohn Disease/Crohn Disease/*drug therapy

• Source: BioMed research international [Biomed Res Int] 2013; Vol. 2013, pp. 879491. Date of Electronic Publication: 2013 Nov 26.Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). ...

• Authors : Patel, Jatin; Bass, Damon; Beishuizen, Albertus

Subjects: Adult; Humans; COVID-19

تفاصيل العنوان

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.

• Authors : Peyrin-Biroulet, Laurent; Hart, Ailsa; Bossuyt, Peter ...

Subjects: Antibodies, Monoclonal, Humanized; Gastrointestinal Agents; Tumor Necrosis Factor Inhibitors

• Source: The Lancet Gastroenterology and Hepatology, 7 (2), 128-140 (2022-02)

تفاصيل العنوان

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

• Authors : Danese, Silvio; Colombel, Jean-Frederic; Lukas, Milan ...

Subjects: Antibodies, Monoclonal, Humanized; Gastrointestinal Agents; B72HH48FLU (Infliximab)

• Source: The Lancet Gastroenterology and Hepatology, 7 (2), 118-127 (2022-02)

تفاصيل العنوان